Inaugural team of experts to provide valuable insights and guidance on NDA filing of the company’s lead product, VASEBRA™ (celiprolol), for the treatment of vascular Ehlers-Danlos Syndrome, and pivotal clinical studies of ACER-001 in MSUD and UCD CAMBRIDGE, Mass.,...

Company obtains exclusive rights to NDA-enabling clinical data of the company’s lead product, VASEBRA™ (celiprolol), for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) CAMBRIDGE, Mass., December 13, 2016 – Acer Therapeutics Inc., a pharmaceutical company...

Financing will support the regulatory filing for the company’s lead product, VASEBRA™, for the treatment of Vascular Ehlers - Danlos Syndrome, as well as pivotal clinical studies for ACER-001 in MSUD and UCD CAMBRIDGE, MA, May 9, 2016 – Acer Therapeutics Inc., a...

Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, appointed Robert Steiner, M.D. to Chief Medical Officer. In this role, Dr. Steiner will be responsible for driving strategy for and...

Acer Therapeutics Receives Patents in the U.S. and EU for the use of Sodium Phenylbutyrate (NaPB) and Prodrugs for the Potential to Treat Maple Syrup Urine Disease (MSUD)  The United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have...

Inaugural team of experts to provide valuable insights and guidance on NDA filing of the company’s lead product, VASEBRA™ (celiprolol), for the treatment of vascular Ehlers-Danlos Syndrome, and pivotal clinical studies of ACER-001 in MSUD and UCD CAMBRIDGE, Mass.,...

Company obtains exclusive rights to NDA-enabling clinical data of the company’s lead product, VASEBRA™ (celiprolol), for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) CAMBRIDGE, Mass., December 13, 2016 – Acer Therapeutics Inc., a pharmaceutical company...

Financing will support the regulatory filing for the company’s lead product, VASEBRA™, for the treatment of Vascular Ehlers - Danlos Syndrome, as well as pivotal clinical studies for ACER-001 in MSUD and UCD CAMBRIDGE, MA, May 9, 2016 – Acer Therapeutics Inc., a...

Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, appointed Robert Steiner, M.D. to Chief Medical Officer. In this role, Dr. Steiner will be responsible for driving strategy for and...

Acer Therapeutics Receives Patents in the U.S. and EU for the use of Sodium Phenylbutyrate (NaPB) and Prodrugs for the Potential to Treat Maple Syrup Urine Disease (MSUD)  The United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have...